Robert C Gallo

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc A reflection on HIV/AIDS research after 25 years
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Retrovirology 3:72. 2006
  2. ncbi request reprint Commentary remarks on "HIV/AIDS in China"
    Robert C Gallo
    Institute of Human Virology, University of Maryland, USA
    Cell Res 15:823. 2005
  3. ncbi request reprint History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2
    Robert C Gallo
    Institute of Human Virology, Baltimore, MD, USA
    Oncogene 24:5926-30. 2005
  4. ncbi request reprint The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland Baltimore, Baltimore, MD, USA
    Lancet 366:1894-8. 2005
  5. pmc The discovery of the first human retrovirus: HTLV-1 and HTLV-2
    Robert C Gallo
    Institute of Human Virology University of Maryland Biotechnology Institute 701 E, Pratt Street Baltimore, MD 21202, USA
    Retrovirology 2:17. 2005
  6. ncbi request reprint A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic viruses
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute, Department of Microbiology and Immunology and Department of Medicine, School of Medicine, 725 W Lombard Street, Baltimore, MD 21201, USA
    Rev Clin Exp Hematol 7:329-35. 2003
  7. ncbi request reprint Control of HIV-1 infection by soluble factors of the immune response
    Anthony L DeVico
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21202, USA
    Nat Rev Microbiol 2:401-13. 2004
  8. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
  9. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
  10. pmc Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
    Yongjun Guan
    Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 106:3952-7. 2009

Research Grants

Detail Information

Publications44

  1. pmc A reflection on HIV/AIDS research after 25 years
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Retrovirology 3:72. 2006
    ..Dr. Robert C. Gallo provides a personal reflection on the 25 year history of AIDS...
  2. ncbi request reprint Commentary remarks on "HIV/AIDS in China"
    Robert C Gallo
    Institute of Human Virology, University of Maryland, USA
    Cell Res 15:823. 2005
  3. ncbi request reprint History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2
    Robert C Gallo
    Institute of Human Virology, Baltimore, MD, USA
    Oncogene 24:5926-30. 2005
    ..However, following our reports the same virus was isolated in Japan, and both groups provided evidence that HTLV-1 caused ATL, a subclassification of T-cell malignancies first recognized in Japan...
  4. ncbi request reprint The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland Baltimore, Baltimore, MD, USA
    Lancet 366:1894-8. 2005
  5. pmc The discovery of the first human retrovirus: HTLV-1 and HTLV-2
    Robert C Gallo
    Institute of Human Virology University of Maryland Biotechnology Institute 701 E, Pratt Street Baltimore, MD 21202, USA
    Retrovirology 2:17. 2005
    ..These efforts finally yielded success following the discovery of IL-2 and its use to culture adult T cell lymphoma/leukemia cells...
  6. ncbi request reprint A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic viruses
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute, Department of Microbiology and Immunology and Department of Medicine, School of Medicine, 725 W Lombard Street, Baltimore, MD 21201, USA
    Rev Clin Exp Hematol 7:329-35. 2003
    ..HTLV-1, 3. HTLV-2, 4. human immunodeficiency virus and 5. human herpes virus-6 (HHV-6). This report is a brief synopsis of the discoveries of the first human retroviruses, the HTLV...
  7. ncbi request reprint Control of HIV-1 infection by soluble factors of the immune response
    Anthony L DeVico
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21202, USA
    Nat Rev Microbiol 2:401-13. 2004
  8. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
    ..In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1...
  9. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
    ....
  10. pmc Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
    Yongjun Guan
    Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 106:3952-7. 2009
    ..These data suggest that plasma Ab repertoires can underestimate the breadth of humoral immunity, and analyses of B(Mem) should be included in studies correlating Ab specificity with protective immunity to HIV-1...
  11. pmc Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    Antimicrob Agents Chemother 51:2489-96. 2007
    ....
  12. pmc Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases
    Fiorenza Cocchi
    Institute of Human Virology and Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 109:5411-6. 2012
    ..The antiviral mechanisms of these HIV X4-suppressive factors differ from those of the previously described HIV R5-suppressive β chemokines...
  13. doi request reprint Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Antiviral Res 83:86-9. 2009
    ..Combinations of RAPA and CCR5 antagonists could provide an effective means to control drug-resistant R5 HIV in patients, most notably those infected with Maraviroc-resistant viruses...
  14. ncbi request reprint The discovery of HIV as the cause of AIDS
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute and University of Maryland, Baltimore, USA
    N Engl J Med 349:2283-5. 2003
  15. pmc Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens
    Anthony Devico
    Basic Research and Vaccine and Epidemiology Divisions, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 104:17477-82. 2007
    ..Collectively, these data suggest that antibodies to CD4i epitopes may play a role in controlling SHIV infection and provide insights for HIV vaccine development...
  16. ncbi request reprint HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation
    Anjana Yadav
    Division of Basic Science, Institute of Human Virology, University of Maryland, Rm S616, 725, West Lombard Street, Baltimore, MD 21201, USA
    Virology 353:357-65. 2006
    ..These events likely lead to defects in antigen-specific signaling and may help explain the disruption of Th1 responses and the generation of specific effector/memory subsets in transgenic CD4+ T cells...
  17. pmc Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding
    Yongjun Guan
    Division of Basic Science and Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 110:E69-78. 2013
    ..Thus, Fc-mediated effector function and neutralization coselect with specificity in anti-Env antibody responses, but the nature of selection is distinct for these two antiviral activities...
  18. ncbi request reprint Historical essay. The early years of HIV/AIDS
    Robert C Gallo
    Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA
    Science 298:1728-30. 2002
  19. ncbi request reprint Differential polarization of immune responses by co-administration of antigens with chemokines
    Achim Frauenschuh
    Division of Basic Science, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, Baltimore, MD 21201, USA
    Vaccine 23:546-54. 2004
    ..These results are relevant towards the engineering of novel vaccine and immune-based therapies, and point to chemokines as candidate adjuvant and immunomodulatory molecules...
  20. ncbi request reprint Historical essay. Prospects for the future
    Robert C Gallo
    Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland, Baltimore, MD 21201, USA
    Science 298:1730-1. 2002
  21. pmc Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5
    Tina M Kish-Catalone
    Division of Basic Sciences, Institute of Human Virology, University of Maryland Biotechnology Institute, 725 West Lombard Street, S622, Baltimore, MD 21201, USA
    Antimicrob Agents Chemother 50:1497-509. 2006
    ..Overall, these preclinical studies suggest that -2 RANTES is suitable for further testing as a candidate anti-HIV-1 microbicide...
  22. ncbi request reprint Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    AIDS 19:2087-95. 2005
    ..To evaluate the effects of the cyclin dependent kinase (CDK) inhibitor Indirubin-3'-monoxime (IM) on Tat-mediated transactivation function, a step of the HIV-1 cycle that is not currently targeted in antiviral therapy...
  23. pmc Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy
    Mikulas Popovic
    Institute of Human Virology, University of Maryland Biotechnology Institute, University of Maryland, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 102:14807-12. 2005
    ....
  24. ncbi request reprint HIV/AIDS research after HAART
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland, USA
    Res Initiat Treat Action 11:39-41. 2005
  25. pmc HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses
    Sayed F Abdelwahab
    Institute of Human Virology, Biotechnology Institute, and Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 100:15006-10. 2003
    ..The data also suggest that production of such factors should be considered in the design of vaccines against HIV-1 and as a mechanism whereby the host can control infections with this virus...
  26. ncbi request reprint HIV-1: a look back from 20 years
    Robert C Gallo
    Institute of Human Virology, University of Maryland Biotechnology Institute and Department of Microbiology, University of Maryland Baltimore, 725 W Lombard Street, Baltimore, MD 21201, USA
    DNA Cell Biol 23:191-2. 2004
  27. ncbi request reprint Human retroviruses after 20 years: a perspective from the past and prospects for their future control
    Robert C Gallo
    Institute of Human Virology, Department of Microbiology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Immunol Rev 185:236-65. 2002
    ....
  28. ncbi request reprint A perspective on human herpes virus 6 (HHV-6)
    Robert C Gallo
    Institute of Human Virology, University of Maryland, Baltimore, MD, USA
    J Clin Virol 37:S2. 2006
  29. ncbi request reprint Commentary on "Prevalence and evolution of drug resistance HIV-1 variants in Henan, China"
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA
    Cell Res 15:850-1. 2005
  30. ncbi request reprint Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments
    David M Hone
    Divisions of Basic Science and Vaccine Research, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Hum Virol 5:17-23. 2002
    ..This paper reviews recent advances made by the authors toward the development of an HIV-1 vaccine that elicits such antibodies in both the mucosal and systemic immune compartments...
  31. ncbi request reprint International NeuroAIDS: prospects of HIV-1 associated neurological complications
    J Roberto Trujillo
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD 21201, USA
    Cell Res 15:962-9. 2005
    ....
  32. ncbi request reprint HIV-1 transgenic rats develop T cell abnormalities
    William Reid
    Division of Basic Science, University of Maryland, Baltimore, MD 21201, USA
    Virology 321:111-9. 2004
    ....
  33. pmc Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein
    Tracy J Ruckwardt
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W Lombard St, Room N546, Baltimore, MD 21201, USA
    J Virol 78:13190-6. 2004
    ..Tat-neutralizing antibodies to the dominant amino terminus epitope are affected by HIV clade variation...
  34. doi request reprint Research and discovery of the first human cancer virus, HTLV-1
    Robert C Gallo
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Best Pract Res Clin Haematol 24:559-65. 2011
    ....
  35. ncbi request reprint HIV receptors on lymphocytes
    Alfredo Garzino-Demo
    Institute of Human Virology, University of Maryland Biotechnology Institute Baltimore, Maryland 21201, USA
    Curr Opin Hematol 10:279-83. 2003
    ..This article reviews the most exciting aspects of these novel findings and discusses their practical application in the fight against HIV infection...
  36. ncbi request reprint Public health. A sound rationale needed for phase III HIV-1 vaccine trials
    Dennis R Burton
    Scripps Research Institute, La Jolla, California, USA
    Science 303:316. 2004
  37. ncbi request reprint Robert C. Gallo, M.D. [Interview by Vicki P Glaser]
    Robert C Gallo
    J Hematother Stem Cell Res 11:751-7. 2002
  38. pmc HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor
    Maria A De Francesco
    Institute of Microbiology, University of Brescia Medical School, 25123 Brescia, Italy
    Proc Natl Acad Sci U S A 99:9972-7. 2002
    ..Our results define a role for p17 in HIV-1 pathogenesis and contribute to our understanding of the molecular mechanism of HIV-1 infection and the development of additional antiviral therapeutic strategies...
  39. doi request reprint Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients
    Clara Lehmann
    First Department of Internal Medicine, University of Cologne, Cologne, Germany
    J Acquir Immune Defic Syndr 48:522-30. 2008
    ..On the other hand, high IFN alpha serum levels in HIV-1-infected individuals have been proposed to promote immune hyper-activation and disease progression...
  40. pmc Human herpesvirus 6A accelerates AIDS progression in macaques
    Paolo Lusso
    Unit of Human Virology, San Raffaele Scientific Institute, 20132 Milan, Italy
    Proc Natl Acad Sci U S A 104:5067-72. 2007
    ..Rapid disease development in dually infected animals was heralded by an early depletion of both CD4(+) and CD8(+) T cells. These results provide in vivo evidence that HHV-6A may act as a promoting factor in AIDS progression...
  41. ncbi request reprint Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol. 1977. 119: 131-138
    Francis W Ruscetti
    J Immunol 179:1415-22. 2007
  42. ncbi request reprint Epilogue: a journey with blood cells and viruses
    Robert C Gallo
    J Hematother Stem Cell Res 11:849-57. 2002
  43. doi request reprint [Kinoids: a novel generation of specific immune therapy against cytokines]
    Armand Bensussan
    Institut National de la Sante et de la Recherche Medicale, INSERM U841, Creteil, France
    Med Sci (Paris) 24:306-13. 2008
    ..After validation by clinical trials, kinoid vaccines could represent a second generation of specific immune therapy to be used to combat ectopic cytokines...
  44. ncbi request reprint A plea for justice for jailed medical workers
    Sunil K Ahuja
    Science 314:924-5. 2006

Research Grants2

  1. Institute of Human Virology Annual Meeting 2002-2004
    Robert Gallo; Fiscal Year: 2002
    ..abstract_text> ..
  2. Institute of Human Virology Annual Meeting 2005-2010
    Robert Gallo; Fiscal Year: 2007
    ..abstract_text> ..